Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Proteomics International Laboratories's cash to debt ratio for the quarter that ended in Dec. 2025 was 16.89.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Proteomics International Laboratoriescould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
ASX:PIQ'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.83 Med: 19.4 Max: No Debt
Current: 16.89
During the past 11 years, Proteomics International Laboratories's highest Cash to Debt Ratio was No Debt. The lowest was 0.83. And the median was 19.40.
ASX:PIQ's Cash-to-Debt is ranked better than 59.42% of 1343
companies
in the Biotechnology industry
Industry Median: 7.25
vs ASX:PIQ: 16.89
Proteomics International Laboratories (ASX:PIQ) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Proteomics International Laboratories Cash-to-Debt Related Terms
Proteomics International Laboratories Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Proteomics International Laboratories Cash-to-Debt Chart
ASX:PIQ vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Proteomics International Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteomics International Laboratories Cash-to-Debt vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories (ASX:PIQ) has a Cash-to-Debt of 16.89 as of Dec. 2025. This is 13% below median its historical median of 19.40. Over the past decade, Proteomics International Laboratories' Cash-to-Debt has ranged from 0.83 to 10,000.00. According to the industry distribution chart, Proteomics International Laboratories ranks #545 out of 1343 companies in the Biotechnology industry, placing it in the top 40.6%.
Is Proteomics International Laboratories' Cash-to-Debt too high?
Proteomics International Laboratories' current Cash-to-Debt of 16.89 is 13% below median its 10-year median of 19.40. Over the past 10 years, this metric has ranged from a low of 0.83 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.25. Proteomics International Laboratories' value of 16.89 is 133% above this industry median. Based on the distribution chart, Proteomics International Laboratories ranks #545 out of 1343 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Proteomics International Laboratories has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Proteomics International Laboratories ranks #545 out of 1343 companies for Cash-to-Debt. This puts Proteomics International Laboratories in the upper half of its industry. The industry median Cash-to-Debt is 7.25. Proteomics International Laboratories' value of 16.89 is 133% above this benchmark. Historically, Proteomics International Laboratories' own Cash-to-Debt has ranged from 0.83 to 10,000.00 over the past decade. While the company's 10-year median is 19.40 vs. the industry median of 7.25, Proteomics International Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.25, based on 1,343 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteomics International Laboratories's current Cash-to-Debt of 16.89 is 133% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteomics International Laboratories's current Cash-to-Debt is 16.89, which is 13% below median its own 10-year median of 19.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Proteomics International Laboratories (ASX:PIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.47, compared to a current price of A$0.17 — trading 64.9% below its estimated fair value. The current Cash-to-Debt is 16.89, which is 13% below median its 10-year median of 19.40 and 133% above the Biotechnology industry median of 7.25. Proteomics International Laboratories' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Proteomics International Laboratories (ASX:PIQ), the current Cash-to-Debt is 16.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Proteomics International Laboratories (ASX:PIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued.
The current stock price of A$0.17 is trading 64.9% below its estimated GF Value™ of A$0.47.
GuruFocus considers Proteomics International Laboratories to be Possible Value Trap.
Key valuation signals for ASX:PIQ:
Cash-to-Debt: 16.89 (13% below median its 10-year median of 19.40)
GF Value™: A$0.47 vs. price of A$0.17 (64.9% below fair value)
Industry Position: 133% above the Biotechnology median (#545 of 1343)
No single metric tells the full story. See the ASX:PIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
25GF Score
Get the complete analysis for ASX:PIQ
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PIQ has been successfully added to your 
